Gilead withdraws Trodelvy in bladder cancer after trial flop
2 days ago · Bladder cancer is a relatively small indication for Trodelvy, representing less than 10% of the drug’s sales, Gilead’s chief financial officer Andrew Dickinson said on the company’s second ...
Gilead Provides Update on U.S. Indication for Trodelvy® in …
3 days ago · Foster City, Calif., October 18, 2024 – Gilead Sciences, Inc. today announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy® (sacituzumab govitecan-hziy; SG) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or ...
Gilead withdraws bladder cancer drug in US after failed trial
2 days ago · Oct 18 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the ...
Gilead Sciences Voluntarily Pulls Drug for Bladder Cancer After …
3 days ago · The withdrawal in metastatic urothelial carcinoma, an aggressive form of bladder cancer, does not affect the drug’s status in its other approved indications in the U.S. or other markets.
Gilead withdraws bladder cancer drug in US after failed trial
(Reuters) -Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the main goal in a confirmatory trial.
Gilead withdraws Trodelvy in bladder cancer | BioPharma Dive
3 days ago · Gilead’s top seller in oncology is the cell therapy Yescarta. But that drug is primarily used to treat blood cancers like lymphoma, while Trodelvy is aimed at a variety of solid tumors. The setback in bladder cancer is a small disappointment, representing less than 10% of sales compared with 90% in breast cancer, TD Securities analyst Tyler ...
Gilead Withdraws ADC Trodelvy in Bladder Cancer After Trial …
2 days ago · Gilead has now decided to take the drug off the market for the indication. Trodelvy’s traditional approvals in different types of advanced breast cancer are not affected by the withdrawal in bladder cancer. The accelerated approval in bladder cancer was granted on Phase II data from the single-arm TROPHY-U-01 study. Gilead conducted the ...
Gilead Sciences to withdraw Trodelvy (sacituzumab govitecan …
2 days ago · The withdrawal wasn’t unexpected. The TROPiCS-04 study, which was meant to serve as the confirmatory trial for the accelerated bladder cancer approval, did not hit its goal. The TROP2-directed antibody-drug conjugate failed to improve on chemotherapy at extending the lives of bladder cancer patients who had tried a PD-1/L1 therapy and chemo.
Gilead Sciences has voluntarily withdrawn Trodelvy from the U.S.
2 days ago · Gilead Sciences announced the voluntary withdrawal of its drug Trodelvy for bladder cancer after it failed to meet survival goals in a confirmatory trial. This decision , made in consultation with the FDA, follows the TROPiCS-04 study, which revealed a higher death rate from complications compared to alternative treatments.
Gilead to Withdraw U.S. Accelerated Approval for Trodelvy in …
2 days ago · Gilead Sciences is pulling its blockbuster breast-cancer drug Trodelvy from use in certain patients with bladder cancer following the failure of a confirmatory study. Gilead on Friday said it ...
- Some results have been removed